Your browser doesn't support javascript.
loading
SARS-CoV-2 Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults.
Levy, Matthew E; Burrows, Evanette; Chilunda, Vanessa; Pawloski, Pamala A; Heaton, Phillip R; Grzymski, Joseph; Goldman, Jason D; McEwen, Lisa M; Wyman, Dana; Dei Rossi, Andrew; Dai, Hang; Isaksson, Magnus; Washington, Nicole L; Basler, Tracy; Tsan, Kevin; Nguyen, Jason; Ramirez, Jimmy; Sandoval, Efren; Lee, William; Lu, James; Luo, Shishi.
Affiliation
  • Levy ME; Helix, San Mateo, California, USA.
  • Burrows E; Helix, San Mateo, California, USA.
  • Chilunda V; Helix, San Mateo, California, USA.
  • Pawloski PA; HealthPartners Institute, Minneapolis, Minnesota, USA.
  • Heaton PR; Department of Pathology and Laboratory Medicine, HealthPartners, Bloomington, Minnesota, USA.
  • Grzymski J; Department of Internal Medicine, University of Nevada Reno, School of Medicine, Reno, Nevada, USA.
  • Goldman JD; Renown Health, Reno, Nevada, USA.
  • McEwen LM; Providence St. Joseph Health System, Renton, Washington, USA.
  • Wyman D; Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, Washington, USA.
  • Dei Rossi A; Division of Infectious Disease, University of Washington, Seattle, Washington, USA.
  • Dai H; Helix, San Mateo, California, USA.
  • Isaksson M; Helix, San Mateo, California, USA.
  • Washington NL; Helix, San Mateo, California, USA.
  • Basler T; Helix, San Mateo, California, USA.
  • Tsan K; Helix, San Mateo, California, USA.
  • Nguyen J; Helix, San Mateo, California, USA.
  • Ramirez J; Helix, San Mateo, California, USA.
  • Sandoval E; Helix, San Mateo, California, USA.
  • Lee W; Helix, San Mateo, California, USA.
  • Lu J; Helix, San Mateo, California, USA.
  • Luo S; Helix, San Mateo, California, USA.
Clin Infect Dis ; 78(6): 1531-1535, 2024 Jun 14.
Article in En | MEDLINE | ID: mdl-38170452
ABSTRACT
Within a multistate clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among nonhospitalized patients with SARS-CoV-2 with risk factors for severe COVID-19. Among 3247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2024 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2024 Document type: Article Affiliation country: United States